| Title |
Src Family Kinase Inhibition as a Novel Strategy to Augment Melphalan-Based Regional Chemotherapy of Advanced Extremity Melanoma
|
|---|---|
| Published in |
Annals of Surgical Oncology, November 2013
|
| DOI | 10.1245/s10434-013-3387-6 |
| Pubmed ID | |
| Authors |
Yoshihiro Tokuhisa, Michael E. Lidsky, Hiroaki Toshimitsu, Ryan S. Turley, Georgia M. Beasley, Tomio Ueno, Ketan Sharma, Christina K. Augustine, Douglas S. Tyler |
| Abstract |
Src kinase inhibition has been shown to augment the efficacy of chemotherapy. Dasatinib, a dual Src/Abl kinase inhibitor approved for the treatment of CML, is under investigation as monotherapy for tumors with abnormal Src signaling, such as melanoma. The goal of this study was to determine if Src kinase inhibition using dasatinib could enhance the efficacy of regionally administered melphalan in advanced extremity melanoma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 3 | 21% |
| Other | 2 | 14% |
| Professor | 2 | 14% |
| Student > Doctoral Student | 1 | 7% |
| Student > Bachelor | 1 | 7% |
| Other | 2 | 14% |
| Unknown | 3 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 29% |
| Biochemistry, Genetics and Molecular Biology | 3 | 21% |
| Agricultural and Biological Sciences | 2 | 14% |
| Nursing and Health Professions | 1 | 7% |
| Chemistry | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 3 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2013.
All research outputs
#20,211,690
of 22,733,113 outputs
Outputs from Annals of Surgical Oncology
#5,480
of 6,437 outputs
Outputs of similar age
#266,989
of 306,502 outputs
Outputs of similar age from Annals of Surgical Oncology
#62
of 70 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,437 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,502 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.